[ad_1]
The results of clinical trials showed that the new anti-coronavirus vaccine produced by the American company “Novavax” is safe and provides an immune response, according to a study published in the scientific journal “New England Journal of Medicine”, this Wednesday.
During the experiments, scientists gave the vaccine and a fake substance to 131 volunteers under the age of 60 last May, where 83 people received the vaccine with an adjuvant to enhance the body’s immune response, while another 25 received a vaccine without adjuvants. and the rest received a placebo vaccine.
The volunteers, all from Australia, also received a second dose 21 days after receiving the first dose.
The researchers said that after 35 days of receiving the booster shot, the volunteers did not experience any serious symptoms.
They added that one person, for example, reported having a mild fever that lasted a day after the second injection.
Otherwise, most of them had no reaction, or if they did, it was mild, some experienced headaches, fatigue, and discomfort for an average of two days or less, and others also experienced fatigue, malaise, and some mild pain in the joints. .
And the scientists, who conducted the experiments, confirm that the vaccine generates an immune response, since all the volunteers who received the vaccine developed antibodies after the second dose.
The results showed that the volunteers, who received two doses of the vaccine with the adjuvant, developed antibodies equivalent to levels four to six times the average of the antibodies developed by people who recovered from Covid-19.
Maryland-based biotech company Novavax will launch the third test phase (the last and largest) this fall, to include 30,000 participants.
Last July, the United States government announced the grant of $ 1.6 billion to the company’s laboratories to develop a Covid-19 vaccine project, which guarantees the United States’ preference for obtaining the first 100 million doses if its effectiveness is demonstrated.
The United States has already contributed more than $ 2 billion to vaccine projects for Johnson & Johnson (456 million), Moderna (483 million) and AstraZeneca (1.2 billion in partnership with Oxford).
